• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Janet Woodcock in the Running for FDA Chief in Biden Administration

Janet Woodcock in the Running for FDA Chief in Biden Administration

January 18, 2021

FDA veteran Janet Woodcock has reportedly been short-listed by the incoming Biden administration to serve as the agency’s next commissioner and will also likely serve as acting chief until the position is filled.

Woodcock is expected to assume the role of acting FDA commissioner on Jan. 20 after President-elect Biden is inaugurated and current chief Stephen Hahn steps down from the agency.

Woodcock, who took leave from her position as director of the agency’s Center for Drug Evaluation and Research (CDER) to serve as the COVID-19 therapeutics adviser to the Trump administration’s Operation Warp Speed (OWS) initiative, is now reportedly being considered to lead the agency in a permanent capacity.

The long-time CDER director just last week returned to the FDA as principal medical adviser to Hahn and is now performing her OWS duties in addition to her new advisory role at the agency.

But Woodcock is not the only candidate on the Biden team’s short list for FDA commissioner. Joshua Sharfstein is also reportedly in the running for the post. A physician with an extensive public health background, Sharfstein previously served as FDA principal deputy commissioner from 2009 to 2011 and led former President Obama’s FDA transition team. He is currently vice dean for public health practice and community engagement at Johns Hopkins Bloomberg School of Public Health.

The Biden transition team did not respond to requests for confirmation of the shortlisted candidates and the FDA declined to comment.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing